#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: melanoma
Long-term survival improved with use of tebentafusp for metastatic uveal melanoma
1. Across a median follow-up of 48.5 months, usage of tebentafusp for patients with metastatic uveal melanoma was associated with ...
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
1. The event-free survival at 12 months was 83.7% in the neoadjuvant group vs 57.2% in the adjuvant group. 2. ...
Neoadjuvant Dual vs Single Checkpoint Inhibitors in High-Risk Melanoma
1. The pathological response rate had an OR of 3.16 when comparing neoadjuvant dual vs single checkpoint inhibitors. 2. The ...
Individualized cancer mRNA-based cancer therapy shows benefit in patients with high-risk melanoma on immunotherapy
1. 18-month recurrence-free survival was significantly greater in the combination therapy group compared to pembrolizumab alone. 2. There were no ...
#VisualAbstract: Treatment of metastatic uveal melanoma with tebentafusp compared to standard treatment
1. Median overall survival and progression-free survival were greater in the tebentafusp group compared to the control group. 2. Adverse ...
Adjuvant treatment with programmed cell death receptor-1 inhibitor pembrolizumab is an effective adjuvant treatment for stage III/IV melanoma
1. Five-year disease-free survival was greater in patients who had ≤10% viable tumour or brisk tumour-infiltrating lymphocytes 2. Overall survival ...
Delay of surgical treatment for melanoma up to 90 days not associated with poorer outcomes
1. In this retrospective cohort study, cutaneous melanomas with a classification of T1b-T4 but without clinical evidence of metastatic disease (N0M0) ...
The Scan by 2 Minute Medicine®: Millions off Medicaid, Hugh Jackman’s Skin Cancer Scare, Artemis II Crew, Earth Day
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
Click to read this study in The Lancet Oncology.
